Bone metastasis: can osteoclasts be excluded?

Area of Science:

• Oncology
• Bone Biology
• Signaling Pathways

Background:

• The RANK/RANKL pathway is crucial for osteoclast function and is a target for inhibiting bone metastasis.
• Inhibitors like OPG are known to suppress bone metastases, primarily attributed to their anti-osteoclast effects.

Discussion:

• Jones et al. reported that OPG inhibits B16F10 melanoma bone metastasis independently of osteoclast resorption.
• Their findings suggest OPG acts via RANK to influence cancer cell migration, a mechanism distinct from osteoclast modulation.

Key Insights:

• This study challenges the established role of osteoclasts in mediating the effects of RANKL inhibitors on bone metastasis.
• The proposed RANK-mediated effect on cancer cell migration offers a new perspective on metastasis.
• The authors critically evaluate the evidence presented by Jones et al., questioning the robustness of their conclusions.

Outlook:

• Further research is needed to validate the proposed RANK-dependent cell migration mechanism in bone metastasis.
• Clarifying the precise role of RANK signaling in cancer cell behavior within the bone microenvironment is essential.
• Re-evaluation of existing data and new experimental designs may be required to fully understand OPG's multifaceted actions.